Search Within

William Douglas Tap

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (42)
  2. Meeting Abstract (37)
  3. Research Letter (1)
Groups
  1. Department of Medicine (80)
  2. Epidemiology and Biostatistics (80)
  3. Sarcoma Service (80)
  4. Solid Tumor Oncology Division (80)
  5. Biostatistics Service (72)
  6. GSK Faculty (69)

More Groups

People
  1. Mark Dickson (61)
  2. Li-Xuan Qin (59)
  3. Sandra D'Angelo (59)
  4. Mary Keohan (55)
  5. Mrinal Gounder (54)
  6. Ping Chi (46)

More People

Years
  1. 2025 (2)
  2. 2024 (8)
  3. 2023 (9)
  4. 2022 (13)
  5. 2021 (4)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (32)
  2. Clinical Cancer Research (8)
  3. Annals of Oncology (5)
  4. European Journal of Cancer (3)
  5. The Oncologist (3)
  6. JAMA Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (34)
  2. American Association for Cancer Research (11)
  3. Oxford University Press (8)
  4. Elsevier Inc. (6)
  5. Nature Publishing Group (6)
  6. Springer (3)

More Publishers

Results (80)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase Ib/II study of imatinab and everolimus in patients with PDGFRA plus synovial sarcoma
    Meeting Abstract

    Keohan, M. L.; Tap, W. D.; Dickson, M. A.; D'Angelo, S. P.; Carvajal, R. D.; Gounder, M. M.; Morales, R. E.; Condy, M. M.; Hameed, M.; Ho, A. L.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma
    Meeting Abstract

    Dickson, M. A.; Tap, W. D.; Keohan, M. L.; D'Angelo, S. P.; Gounder, M. M.; Chi, P.; Antonescu, C. R.; Landa, J.; Qin, L. X.; Rathbone, D. D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Poor prognostic features in angiosarcoma: A single institution retrospective study of 324 patients
    Meeting Abstract

    D'Angelo, S. P.; Moraco, N. H.; Qin, L. X.; Kuk, D.; Carvajal, R. D.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Antonescu, C. R.; Singer, S.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Final results of sequential phase 2 studies of palbociclib (PD0332991) in CDK4-amplified liposarcoma
    Meeting Abstract

    Dickson, M.; Tap, W. D.; Antonescu, C. R.; Landa, J.; Qin, L. X.; Crago, A. M.; Singer, S.; Schwartz, G. K.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • High-risk features in radiation-associated breast angiosarcomas
    Journal Article

    D'Angelo, S. P.; Antonescu, C. R.; Kuk, D.; Qin, L.; Moraco, N.; Carvajal, R. D.; Chi, P.; Dickson, M. A.; Gounder, M.; Keohan, M. L.; more...
    British Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
    Journal Article

    Dickson, M. A.; Tap, W. D.; Keohan, M. L.; D'Angelo, S. P.; Gounder, M. M.; Antonescu, C. R.; Landa, J.; Qin, L. X.; Rathbone, D. D.; Condy, M. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial
    Journal Article

    Schwartz, G. K.; Tap, W. D.; Qin, L. X.; Livingston, M. B.; Undevia, S. D.; Chmielowski, B.; Agulnik, M.; Schuetze, S. M.; Reed, D. R.; Okuno, S. H.; more...
    Lancet Oncology (2013)

    Fulltext@MSK | Save
  • A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS)
    Meeting Abstract

    Schwartz, G. K.; Tap, W. D.; Qin, L. X.; Livingston, M. B.; Undevia, S. D.; Chmielowski, B.; Agulnik, M.; Schuetze, S.; Reed, D. R.; Okuno, S. H.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A first-in-human, phase Ib combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcoma
    Meeting Abstract

    Gounder, M. M.; Dickson, M. A.; Wu, N.; Ivy, S. P.; Carvajal, R. D.; D'Angelo, S. P.; Keohan, M. L.; Qin, L. X.; Erinjeri, J. P.; Takebe, N.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma
    Meeting Abstract

    Dickson, M. A.; Keohan, M. L.; Tap, W. D.; Antonescu, C.; Landa, J.; Qin, L. X.; Dohrenwend, E. G.; Rathbone, D.; Ustoyev, Y.; Condy, M. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save